Moksonydyn | Physiotens tablets are covered. 0.4 mg 28 pcs.
Special Price
$29.10
Regular Price
$37.00
In stock
SKU
BID518917
Pharmacological action
Antihypertensive agent. The mechanism of action of moxonidine is mainly associated with its effect on the central links of blood pressure regulation. Moxonidine is an agonist of predominantly imidazoline receptors.
By exciting these solitary tract neuron receptors, moxonidine through the inhibitory interneuron system helps to inhibit the activity of the vasomotor center and thus reduce the downward sympathetic effects on the cardiovascular system. Blood pressure (systolic and diastolic) decreases gradually. Moxonidine differs from other sympatholytic antihypertensive agents in a lower affinity for ОІ2-adrenergic receptors, which explains the lower likelihood of developing a sedative effect and dry mouth.
moxonidine boosts chuv indexinsulin resistance (compared with placebo) by 21% in patients with obesity, insulin resistance and a moderate degree of arterial hypertension.
Antihypertensive agent. The mechanism of action of moxonidine is mainly associated with its effect on the central links of blood pressure regulation. Moxonidine is an agonist of predominantly imidazoline receptors.
By exciting these solitary tract neuron receptors, moxonidine through the inhibitory interneuron system helps to inhibit the activity of the vasomotor center and thus reduce the downward sympathetic effects on the cardiovascular system. Blood pressure (systolic and diastolic) decreases gradually. Moxonidine differs from other sympatholytic antihypertensive agents in a lower affinity for ОІ2-adrenergic receptors, which explains the lower likelihood of developing a sedative effect and dry mouth.
moxonidine boosts chuv indexinsulin resistance (compared with placebo) by 21% in patients with obesity, insulin resistance and a moderate degree of arterial hypertension.
Pharmacological action
Antihypertensive agent. The mechanism of action of moxonidine is mainly associated with its effect on the central links of blood pressure regulation. Moxonidine is an agonist of predominantly imidazoline receptors.
By exciting these solitary tract neuron receptors, moxonidine through the inhibitory interneuron system helps to inhibit the activity of the vasomotor center and thus reduce the downward sympathetic effects on the cardiovascular system. Blood pressure (systolic and diastolic) decreases gradually. Moxonidine differs from other sympatholytic antihypertensive agents in a lower affinity for ОІ2-adrenergic receptors, which explains the lower likelihood of developing a sedative effect and dry mouth.
moxonidine boosts chuv indexinsulin resistance (compared with placebo) by 21% in patients with obesity, insulin resistance and a moderate degree of arterial hypertension.
Indications
Arterial hypertension.
Contraindications
Severe bradycardia (less than 50 beats / min), CVD, AV block II and III degree, acute and chronic heart failure, lactation (breastfeeding), children and adolescents under 18 years, hypersensitivity to moxonidine .
Special instructions
Special care must be taken when using moxonidine in patients with degree I AV block (risk of developing bradycardia) with severe coronary artery disease and unstable angina (insufficient experience) with renal failure.
If it is necessary to cancel the simultaneously taken beta-blockers and moxonidine, first beta-blockers are canceled and only after a few days - moxonidine.
There is currently no evidence that discontinuation of moxonidine leads to an increase in blood pressure. However, abrupt cessation of taking moxonidine is not recommended, the dose should be reduced gradually, within 2 weeks.
Influence on the ability to drive vehicles and control mechanisms
During treatment, patients should be careful when they need to engage in potentially dangerous activities that require concentration and a high speed of psychomotor reactions.
Composition
1 tab. moxonidine 0.4 mg
Excipients: lactose monohydrate - 95.6 mg, povidone - 0.7 mg, crospovidone - 3 mg, magnesium stearate - 0.3 mg.
Shell composition: hypromellose - 1.3 mg, ethyl cellulose - 1.2 mg, macrogol - 0.25 mg, talc - 0.875 mg, dye iron oxide red (E172) - 0.125 mg, titanium dioxide (E171) - 1.25 mg.
Dosage and administration
Take orally. The initial dose is on average 200 mcg orally 1 time / day. The maximum single dose is 400 mcg. An individual correction of the daily dose is necessary depending on the tolerability of therapy. The maximum daily dose is 600 mcg in 2 divided doses.
For patients with moderate to severe renal failure, as well as those on hemodialysis, the initial dose is 200 mcg / day. If necessary and with good tolerance, the daily dose can be increased to a maximum of 400 mcg.
Side effects
From the central nervous system: often - headache, dizziness (vertigo), drowsiness infrequently - fainting.
From the cardiovascular system: infrequently - a marked decrease in blood pressure, orthostatic hypotension, bradycardia.
From the digestive system: very often - dry mouth often - diarrhea, nausea, vomiting, dyspepsia.
From the skin and subcutaneous tissues: often - skin rash, itching infrequently - angioedema.
From the psyche: often - insomnia infrequently - nervousness.
On the part of the hearing organ and labyrinth disorders: infrequently - ringing in the ears.
From the musculoskeletal system: often - back pain infrequently - pain in the neck.
On the part of the body as a whole: often - asthenia infrequently - peripheral edema.
Active ingredient
Moxonidine
Terms of delivery from
pharmacies Prescription
dosage form
tablets
Nobel Almaty Pharmaceutical Factory AO, USA
Antihypertensive agent. The mechanism of action of moxonidine is mainly associated with its effect on the central links of blood pressure regulation. Moxonidine is an agonist of predominantly imidazoline receptors.
By exciting these solitary tract neuron receptors, moxonidine through the inhibitory interneuron system helps to inhibit the activity of the vasomotor center and thus reduce the downward sympathetic effects on the cardiovascular system. Blood pressure (systolic and diastolic) decreases gradually. Moxonidine differs from other sympatholytic antihypertensive agents in a lower affinity for ОІ2-adrenergic receptors, which explains the lower likelihood of developing a sedative effect and dry mouth.
moxonidine boosts chuv indexinsulin resistance (compared with placebo) by 21% in patients with obesity, insulin resistance and a moderate degree of arterial hypertension.
Indications
Arterial hypertension.
Contraindications
Severe bradycardia (less than 50 beats / min), CVD, AV block II and III degree, acute and chronic heart failure, lactation (breastfeeding), children and adolescents under 18 years, hypersensitivity to moxonidine .
Special instructions
Special care must be taken when using moxonidine in patients with degree I AV block (risk of developing bradycardia) with severe coronary artery disease and unstable angina (insufficient experience) with renal failure.
If it is necessary to cancel the simultaneously taken beta-blockers and moxonidine, first beta-blockers are canceled and only after a few days - moxonidine.
There is currently no evidence that discontinuation of moxonidine leads to an increase in blood pressure. However, abrupt cessation of taking moxonidine is not recommended, the dose should be reduced gradually, within 2 weeks.
Influence on the ability to drive vehicles and control mechanisms
During treatment, patients should be careful when they need to engage in potentially dangerous activities that require concentration and a high speed of psychomotor reactions.
Composition
1 tab. moxonidine 0.4 mg
Excipients: lactose monohydrate - 95.6 mg, povidone - 0.7 mg, crospovidone - 3 mg, magnesium stearate - 0.3 mg.
Shell composition: hypromellose - 1.3 mg, ethyl cellulose - 1.2 mg, macrogol - 0.25 mg, talc - 0.875 mg, dye iron oxide red (E172) - 0.125 mg, titanium dioxide (E171) - 1.25 mg.
Dosage and administration
Take orally. The initial dose is on average 200 mcg orally 1 time / day. The maximum single dose is 400 mcg. An individual correction of the daily dose is necessary depending on the tolerability of therapy. The maximum daily dose is 600 mcg in 2 divided doses.
For patients with moderate to severe renal failure, as well as those on hemodialysis, the initial dose is 200 mcg / day. If necessary and with good tolerance, the daily dose can be increased to a maximum of 400 mcg.
Side effects
From the central nervous system: often - headache, dizziness (vertigo), drowsiness infrequently - fainting.
From the cardiovascular system: infrequently - a marked decrease in blood pressure, orthostatic hypotension, bradycardia.
From the digestive system: very often - dry mouth often - diarrhea, nausea, vomiting, dyspepsia.
From the skin and subcutaneous tissues: often - skin rash, itching infrequently - angioedema.
From the psyche: often - insomnia infrequently - nervousness.
On the part of the hearing organ and labyrinth disorders: infrequently - ringing in the ears.
From the musculoskeletal system: often - back pain infrequently - pain in the neck.
On the part of the body as a whole: often - asthenia infrequently - peripheral edema.
Active ingredient
Moxonidine
Terms of delivery from
pharmacies Prescription
dosage form
tablets
Nobel Almaty Pharmaceutical Factory AO, USA
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review